Skip to main content
HLS Therapeutics Inc. logo

HLS Therapeutics Inc. — Investor Relations & Filings

Ticker · HLS ISIN · US40390B3078 LEI · 549300QKXFY1J71L2D68 TSX Wholesale and retail trade
Open in API
Filings indexed 189 across all filing types
Latest filing 2026-04-24 Proxy Solicitation & In…
Country CA Canada
Listing TSX HLS

About HLS Therapeutics Inc.

https://hlstherapeutics.com/

HLS Therapeutics Inc. is a specialty pharmaceutical company focused on the acquisition and commercialization of branded medicines across North America. The company targets products that address unmet needs, primarily in the treatment of psychiatric disorders and cardiovascular disease/risk reduction. Its commercial-stage portfolio includes CLOZARIL® (clozapine) for psychiatric disorders and VASCEPA® (icosapent ethyl) for cardiovascular risk reduction. HLS also commercializes NILEMDO® (bempedoic acid) and NEXLIZET® (bempedoic acid/ezetimibe combination) for the reduction of LDL-cholesterol in patients at risk of cardiovascular disease. HLS ensures reliable market access to these essential therapies by sourcing products directly from originators and best-in-class manufacturing partners.

Recent filings

Filing Released Lang Actions
Notice of the meeting and record date - English.pdf
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal notice regarding the Annual General Meeting of security holders, including record dates, meeting date/location, proxy materials distribution, and Notice and Access details. These are classic elements of proxy solicitation materials (materials sent to shareholders to provide information and request votes ahead of a meeting). Therefore it falls under Proxy Solicitation & Information Statement (PSI).
2026-04-24 English
Notice of the meeting and record date - English.pdf
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a notice regarding the upcoming Annual General Meeting of security holders, detailing meeting type, record dates, voting instructions, and proxy delivery arrangements. It serves as part of the proxy solicitation materials (Notice and Access) provided to regulators (and ultimately shareholders) to facilitate voting. This aligns with the Proxy Solicitation & Information Statement category.
2026-04-24 English
News release - English.pdf
Regulatory Filings Classification · 0% confidence The document is a corporate press release announcing that HLS’s CEO will present at an investor conference. It is neither a financial report (10-K, IR, ER), nor a management or governance filing, nor a dividend or capital update, nor a shareholder vote notice. It does not include the actual investor presentation deck, so it is not categorized as an IP. This is a general regulatory announcement/fallback, so it should be classified as RNS.
2026-04-14 English
News release - English.pdf
Investor Presentation Classification · 1% confidence The document is a press release announcing that HLS Therapeutics’ CEO will present at the 2026 Bloom Burton & Co. Healthcare Investor Conference, including date, time, and webcast details. It is not an earnings release, quarterly or annual report, or regulatory filing, but clearly pertains to an upcoming investor presentation event. Therefore, it fits the Investor Presentation category (IP).
2026-04-14 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a press release announcing an upcoming presentation by the CEO at an investor conference, without providing actual presentation materials or detailed slides. It does not constitute a formal investor presentation deck (IP) nor any specific financial report, earnings release, or regulatory notice. As a general IR announcement that doesn’t fit the specific categories, it falls into the fallback “Regulatory Filings” category (RNS).
2026-04-14 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a press release issued by HLS Therapeutics announcing a regulatory milestone (Health Canada approval of a drug). It provides details on the drug's clinical trial data, commercial launch plans, and the status of a related product submission. This type of corporate announcement regarding product development and regulatory status is classified as a general regulatory filing or corporate news announcement, which falls under the 'RNS' (Regulatory Filings) category in the provided schema.
2025-11-18 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.